2018 American Transplant Congress » Poster Session B: PTLD/Malignancies: All Topics

6:00pm-7:00pm

A Population Based Study of Incidence of Post Kidney Transplant Malignancies

D. Sexton,¹ J. O'Neill,² P. O'Kelly,¹ S. Murray,¹ S. Deady,³ E. O'Leary,³ P. Morris,⁴ P. Conlon.¹

6:00pm-7:00pm

Cancer Incidence after Kidney Transplantation in Saudi Arabia, Comparing Different Induction Agents

H. AlEid, S. Raza, T. Ali, I. Alahmadi, S. Aleid, D. Broering.

6:00pm-7:00pm

Decreased Expression of Pro-Carcinogenic Genes Following Tacrolimus to Sirolimus Conversion in Liver Transplant Recipients

M. Bhat,¹ E. Pasini,¹ C. Baciu,¹ S. Kurian,² J. Levitsky.³

6:00pm-7:00pm

Evaluating the Impact of Pre-Transplant Malignancy on Outcomes after Kidney Transplantation: A National Database Analysis over a Twenty-Two Year Period

D. Livingston-Rosanoff, L. Wilke, G. Leverson, D. Foley.

6:00pm-7:00pm

Follow-Up and Outcomes of Epstein-Barr Virus Negative Recipients after a Kidney Transplant from an Epstein-Barr Virus Positive Donor

C. Dudreuilh, E. Asgari, R. Hilton.

6:00pm-7:00pm

Genomic Diversity of Epstein Barr Virus in Post-Transplant Lymphoproliferative Disorder

E. Maloney,¹ V. Busque,² S. Hui,² S. Krams,^1,2 C. Esquivel,^1,2 O. Martinez.^1,2

6:00pm-7:00pm

Genomic Modifications Associated with Epstein Barr Virus+ Post-Transplant Lymphoproliferative Disorder

M. McPherson,¹ Y. Balachandran,¹ S. Boyd,² H. Zimmermann,³ R. Trappe,³ C. Esquivel,¹ S. Krams,¹ O. Martinez.¹

6:00pm-7:00pm

Impact of Antecedent Malignancy on Kidney Transplant Outcomes: Patient, Graft, and Cancer-Free Survival

O. Serrano,¹ S. Mongin,² D. Berglund,¹ D. Vock,³ S. Chinnakotla,¹ T. Dunn,¹ E. Finger,¹ R. Kandaswamy,¹ T. Pruett,¹ A. Matas.¹

6:00pm-7:00pm

Incidence of Epstein Barr Virus (EBV) DNAemia in EBV-Seronegative Solid Organ Transplant (SOT) Recipients with EBV-Seropositive Donors

C. Burton,¹ C. Mabilangan,² J. Preiksaitis.²

6:00pm-7:00pm

Induction Agents and Post-Transplant Malignancies in Kidney Transplants: An Examination of Outcomes at a Large Volume Center over 20 Years

D. Livingston-Rosanoff, X. Wang, G. Leverson, D. Kaufman, D. Foley.

6:00pm-7:00pm

Post-Transplant Lymphoproliferative Disorder after Kidney Transplantation: A Single Institute Experience with Focus on Epstein-Barr Virus Status

P. Zhang,¹ R. King,¹ K. Ristow,² L. Cornell,¹ F. Cosio,³ T. Habermann,² M. Alexander.¹

6:00pm-7:00pm

Pre-Existing Renal Cell Carcinomas in Patients with Polycystic Kidney Disease Undergoing Simultaneous Native Nephrectomy and Living Donor Kidney Transplantation

M. Aull,¹ J. Del Pizzo,² A. Watkins,¹ S. Kapur.¹

6:00pm-7:00pm

Presentation and Outcomes of Post-Transplant Proliferative Disorder at a Single Institution Pediatric Transplant Center

G. Ramos-Gonzalez,¹ A. Allain,¹ T. Agur,¹ L. O'Melia,¹ S. Staffa,² S. Burchett,¹ B. Siegele,³ O. Weinberg,³ N. Rodig,¹ R. Fawaz,¹ T. Singh,¹ D. Freiberger,¹ K. Heung Bae.¹

6:00pm-7:00pm

Pretransplant Use of Rituximab is Associated with Posttransplant Malignancies Events and Death by Neoplasia in Incompatibility Living Donor Kidney Transplants

I. Revuelta,^1,2,3,4 V. Tubita,² D. Cucchiari,^1,2 E. De Sousa,¹ P. Piselli,⁵ M. Lozano,⁶ J. Cid,⁶ E. Palou,⁷ J. Martorell,⁷ F. Oppenheimer,^1,2,3,4 F. Diekmann,^1,2,3,4 J. Campistol.^1,2,3,4

6:00pm-7:00pm

Survival, Cancer and PTLD Diagnosis after Late EBV Infection in Adult Kidney Transplantation

M. Morton,¹ G. Scullin,² K. Daga,² P. Klapper,² P. Vallely,² M. Picton.¹

6:00pm-7:00pm

The Influence of a Conversion to Sirolimus-Based Immunosuppression on Non-Melanomatous Skin Cancer Incidence in Kidney Transplant Recipients over Long Term Follow Up

F. Daly,¹ P. O'Kelly,¹ F. Moloney,² D. Sexton,¹ P. Conlon.¹

6:00pm-7:00pm

The MicroRNA Landscape of EBV+ and EBV- PTLD

Y. Balachandran,¹ H. Zimmermann,² C. Esquivel,¹ S. Krams,¹ R. Trappe,² O. Martinez.¹

6:00pm-7:00pm

Tumor Recurrence in Kidney Transplant Recipients with a History of Pretransplant Malignancy

F. Becker,¹ K. Schütte Nütgen,² S. Reuter,² L. Kebschull,¹ T. Vowinkel,¹ N. Senninger,¹ D. Palmes,¹ T. Vogel,¹ R. Bahde.¹

6:00pm-7:00pm

Use of Cyclin-Dependent Kinase Inhibitors to Reduce Gammaherpesvirus Reactivation

J. Hazleton,¹ L. van Dyk.²